Hoe verhoudt RAMM's PS Ratio zich tot zijn concurrenten?

RAMM is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.6x).

Hoe verhoudt RAMM's PS Ratio zich tot andere bedrijven in de CA Pharmaceuticals industrie?

RAMM is good value based on its Price-To-Sales Ratio (0.3x) compared to the Canadian Pharmaceuticals industry average (1x).

Wat is RAMM's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Insufficient data to calculate RAMM's Price-To-Sales Fair Ratio for valuation analysis.

Wat is de reële prijs van RAMM als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Insufficient data to calculate RAMM's fair value for valuation analysis.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Insufficient data to show price forecast.

RAMM Pharma (CNSX:RAMM) - Aandelenkoers, Nieuws & Analyse

RAMM Overzicht aandelen

Over het bedrijf

RAMM fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Risicoanalyse

Does not have a meaningful market cap (CA$1M)

Shares are highly illiquid

Has less than 1 year of cash runway

Earnings have declined by 12.9% per year over past 5 years

+ 1 meer risico

RAMM Pharma Corp. Concurrenten

SLANG Worldwide

CNSX:SLNG

CA$1.1m

Hash

CNSX:REZN

CA$1.4m

Gnomestar Craft

CNSX:GNOM

CA$854.1k

Medcolcanna Organics

CNSX:MCCN

CA$848.7k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor RAMM Pharma
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.01
52 Week Hoogtepunt	CA$0.095
52 Week Laag	CA$0.01
Bèta	-0.21
11 maand verandering	-50.00%
3 maanden verandering	-50.00%
1 Jaar Verandering	-85.71%
33 jaar verandering	-97.89%
5 jaar verandering	-98.33%
Verandering sinds IPO	-98.48%

Recent nieuws en updates

Recent updates

How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

Dec 18

Rendement voor aandeelhouders

	RAMM	CA Pharmaceuticals	CA Markt
7D	0%	-4.7%	-1.5%
1Y	-85.7%	17.0%	21.1%

Rendement versus industrie: RAMM underperformed the Canadian Pharmaceuticals industry which returned 17% over the past year.

Rendement versus markt: RAMM underperformed the Canadian Market which returned 21.1% over the past year.

Prijsvolatiliteit

Is RAMM's price volatile compared to industry and market?
RAMM volatility
RAMM Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: RAMM's share price has been volatile over the past 3 months compared to the Canadian market.

Volatiliteit in de loop van de tijd: Insufficient data to determine RAMM's volatility change over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1987	n/a	Jack Burnett	n/a

RAMM Pharma Corp. houdt zich bezig met onderzoek en ontwikkeling, productie en verkoop van cannabinoïde farmacologie en formuleringen, farmaceutica, cosmetica en nutraceutische producten in Uruguay, Italië en Polen. Het bedrijf houdt zich ook bezig met de wederverkoop van producten voor medische benodigdheden en de verkoop van medische apparaten en verbruiksgoederen en diergeneeskundige producten. Het biedt cosmetische CBD+CBG aan.

RAMM Pharma Corp. Samenvatting

Hoe verhouden de winst en inkomsten van RAMM Pharma zich tot de beurswaarde?
RAMM fundamentele statistieken
Marktkapitalisatie	CA$1.19m
Inkomsten(TTM)	-CA$8.87m
Inkomsten(TTM)	CA$4.47m

0.3x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is RAMM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RAMM resultatenrekening (TTM)
Inkomsten	CA$4.47m
Kosten van inkomsten	CA$3.96m
Brutowinst	CA$508.20k
Overige uitgaven	CA$9.38m
Inkomsten	-CA$8.87m

Laatst gerapporteerde inkomsten

Jul 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.074
Brutomarge	11.37%
Nettowinstmarge	-198.51%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde RAMM op de lange termijn?

Bekijk historische prestaties en vergelijking

RAMM Overzicht aandelen

Beloningen

Risicoanalyse

RAMM Pharma Corp. Concurrenten

CNSX:SLNG

CA$1.1m

CNSX:REZN

CA$1.4m

CNSX:GNOM

CA$854.1k

CNSX:MCCN

CA$848.7k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in 2Q 2023)

RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024

New major risk - Financial position

Full year 2023 earnings released: CA$0.064 loss per share (vs CA$0.17 loss in FY 2022)

New minor risk - Shareholder dilution

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in 2Q 2023)

RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024

New major risk - Financial position

Full year 2023 earnings released: CA$0.064 loss per share (vs CA$0.17 loss in FY 2022)

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.009 loss in 3Q 2022)

RAMM Pharma Corp. Common Shares to Be Deleted from OTC Equity

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.012 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.016 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.17 loss per share (vs CA$0.066 loss in FY 2021)

Insufficient new directors

RAMM Pharma Corp. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings released: CA$0.009 loss per share (vs CA$0.03 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

RAMM Pharma Corp., Annual General Meeting, Apr 07, 2022

High number of new and inexperienced directors

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.018 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.012 loss in 2Q 2020)

RAMM Pharma Corp. (CNSX:RAMM) agreed to acquire the remaining 51% stake in Canapar S.r.L. for approximately $26.2 million.

Jack Burnett, President and a director of Ramm Pharma, Daniel Augereau, a director of Ramm Pharma and an unknown buyer acquired approximately 10% stake in RAMM Pharma Corp. (CNSX:RAMM) from Armando Blankleider for CAD 2.3 million.

First quarter 2021 earnings released: CA$0.015 loss per share (vs CA$0.02 loss in 1Q 2020)

New 90-day high: CA$1.14

Full year 2020 earnings released: CA$0.074 loss per share (vs CA$0.14 loss in FY 2019)

RAMM Pharma Selects as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health

New 90-day high: CA$1.05

Canapar Corp. and RAMM Pharma Corp. enters into Strategic Partnership

New 90-day high: CA$0.75

New 90-day high: CA$0.68

Canopy Rivers Inc. (TSX:RIV) acquired an additional 49% stake in Canapar S.r.L. from RAMM Pharma Corp. (CNSX:RAMM) for $9 million.

How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

New 90-day low: CA$0.45

Ramm Pharma Corp. Commences Sales of Epifractán Products Through Peruvian Pharmacies

Third quarter earnings released

New 90-day high - CA$0.60

New 90-day high - CA$0.54

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

RAMM Pharma Corp. Samenvatting

0.3x

-0.1x

Inkomsten en omzet